SAN ANTONIO — Nice try, ATEMPT investigators, but trastuzumab emtansine (T-DM1) does not have a disease-free survival or safety advantage over paclitaxel plus trastuzumab in the adjuvant setting for ...

PDT 9 (29.0) 13.0 to 45.0 TR 4 (12.9) 1.1 to 24.7 AB 10 (32.3) 15.8 to 48.8 Abbreviations: AB, any benefit; ER, estrogen receptor; PDT, prolonged duration on therapy; PR, progesterone receptor; T-DM1, ...

SAN ANTONIO -- Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib ...

There were no fatal treatment-emergent adverse events (TEAEs) in either patient group, but exposure-adjusted incidence rates ...

Investigational drug linked to Herceptin promising in clinical trials. June 3, 2012— -- For Bridget Spence, graduation from college was a short-lived joy. Just one week after receiving her degree ...

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive ...

ZURICH (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking its experimental "armed antibody" drug without the disease worsening than those on a mix of ...

Ovarian cancer: Data from second positive phase III study of Avastin (ICON7) add further evidence to the potential of Avastin in ovarian cancer where there have been few major treatment advances in ...

Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening In the article that accompanies this editorial, Dzimitrowicz et al 10 provide a real-world glimpse of T-DM1 in patients who ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Among patients with previously treated HER-2–positive locally advanced or metastatic gastric or ...

Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

August 28, 2012 — A novel twist on the targeted agent trastuzumab (Herceptin, Genentech/Roche), known as trastuzumab emtansine (or T-DM1), is a step closer to market. Updated results from a pivotal ...